Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?

Stephanie E. Combs, Stefan Rieken, Wolfgang Wick, Amir Abdollahi, Andreas von Deimling, Jürgen Debus, Christian Hartmann

Research output: Contribution to journalArticlepeer-review

91 Scopus citations

Abstract

A group of 160 patients with primary glioblastoma treated with radiotherapy and temozolomide was analyzed for the impact of O6-methly-guanly-methyl-transferase (MGMT)-promoter methylation as well as isocitrate dehydrogenase (IDH)1-mutational status. Unexpectedly, overall survival or progression-free survival were not longer in the group with methylated MGMT-promoter as compared to patients without that methylation. IDH-1 mutations were significantly associated with increased overall survival.

Original languageEnglish
Article number115
JournalRadiation Oncology
Volume6
Issue number1
DOIs
StatePublished - 2011
Externally publishedYes

Keywords

  • Glioblastoma
  • IDH
  • MGMT
  • Radiation
  • Temozolomide

Fingerprint

Dive into the research topics of 'Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?'. Together they form a unique fingerprint.

Cite this